Real-world treatment outcomes, healthcare resource use, and costs associated with antiemetics among cancer patients on cisplatin-based chemotherapy

Real-world treatment outcomes, healthcare resource use, and costs associated with antiemetics among cancer patients on cisplatin-based chemotherapy

by | May 31, 2023 | Cancer (blood), Cancer (solid tumor), Publication

ABSTRACT Introduction: Chemotherapy-induced nausea and vomiting (CINV) is a recognized adverse outcome among patients with cancer. This retrospective study aimed to quantify the treatment outcomes, resource utilization, and costs associated with antiemetic use to...

Comparison of incidence/occurrence of cardiovascular events between ponatinib vs bosutinib among patients with at least one prior line of tyrosine kinase inhibitors in chronic myeloid leukemia in a community setting in the United States

by | Feb 22, 2022 | Cancer (blood), Publication

Authors: Levy M, Xie L, Wang Y, Neumann F, Srivastava S, Naranjo D, Xu J, Zhang Q, Dalal M Abstract Introduction: In this real-world study, the incidence of cardiovascular events (CV) including major adverse cardiac events (MACE), arterial occlusive events (AOE), and...

Time to next treatment, healthcare resource utilization, and costs associated with ibrutinib use among US veterans with chronic lymphocytic leukemia/small lymphocytic lymphoma: A real-world retrospective analysis

by | Oct 13, 2020 | Cancer (blood), Publication

Abstract Authors: Qing Huang, Sujana Borra, Jieni Li, Li Wang, Sulena Shrestha, Murali Sundaram, Nora Janjan  Background: Chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) is the most common adult leukemia, accounting for ≈ 37% of all leukemias in the...